19.00EUR-0.31%Mkt Cap: 333.66M EURP/E: —Last update: 2026-05-14
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular …
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)17.06
PEG—
P/B0.84
P/S7.50
EV/EBITDA-56.98
EV/Revenue6.17
EPS (TTM)-3.66
EPS (Forward)1.11
Cash Flow & Leverage
FCF Yield-9.14%
FCF Margin-68.55%
Operating CF10.78M EUR
CapEx (TTM)54.89M EUR
Net Debt/EBITDA12.31
Net Debt-59.28M EUR
Technical
SMA 5018.53 (+2.5%)
SMA 20022.29 (-14.7%)
Beta0.65
S&P 52W Chg24.23%
Avg Vol (30d)10.20K
Avg Vol (10d)11.48K
Technical Indicators
RSI (14)52.8
MACD-0.0023
MACD Signal-0.1204
MACD Hist.+0.1181
BB Upper19.72 EUR
BB Middle18.60 EUR
BB Lower17.48 EUR
BB Width12.08%
ATR (14)0.9176 EUR
Vol Ratio (20d)0.59x
52W Range
15.8021% of range31.30
52W High31.30 EUR
52W Low15.80 EUR
Profitability
Gross Margin8.04%
EBITDA Margin-10.83%
Profit Margin-145.46%
Oper. Margin41.40%
ROE-16.21%
ROA-8.75%
Revenue Growth-12.60%
Earnings Growth—
Balance Sheet
Debt/Equity0.02
Current Ratio2.33
Quick Ratio1.89
Book Value/Sh22.59 EUR
Cash/Share3.896 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.17.67M
Float13.36M
Insiders30.00%
Institutions31.26%
Analyst Consensus
Rating—
Target (Mean)40.14 EUR
Target Range30.00 EUR – 53.00 EUR
# Analysts7
Company
Market Cap333.66M EUR
Enterprise Value274.38M EUR
Revenue (TTM)44.48M EUR
Gross Profit3.58M EUR
Net Income (TTM)-64.70M EUR
Revenue/Share2.517 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees—
Last Price19.00 EUR
CountryDE
SectorHealthcare
IndustryBiotechnology
ISINDE000A1EWVY8